Suppr超能文献

运动和药物治疗对非酒精性脂肪性肝病的影响。

Effect of exercise and pharmacotherapy on non-alcoholic fatty liver disease.

作者信息

Kandel Amrita, Pant Poonam, Todi Sushila, Kc Sudhamshu, Pandey Sudip

机构信息

Pharmacy Program, CiST College, New Baneshwor, Kathmandu, Nepal.

Obstetrics and Gynaecology Departments, Patan Academy of Health Sciences, Kathmandu, Nepal.

出版信息

SAGE Open Med. 2024 Jan 25;12:20503121241227090. doi: 10.1177/20503121241227090. eCollection 2024.

Abstract

OBJECTIVES

Nonalcoholic fatty liver disease is one of the emerging liver diseases affecting 20%-30% of the population creating a burden on public health worldwide and has been associated with the causation of multiple diseases. Besides exercise, several drugs are being used in patients based on clinical evidence especially vitamin E, a potent antioxidant to reduce the oxidative stress responsible for the development and progression of nonalcoholic fatty liver disease. This study aims at evaluating the effect of exercise and pharmacotherapy on nonalcoholic fatty liver disease.

DESIGN

A prospective follow-up study with purposive sampling was done at a liver clinic for 3 months. Baseline characteristics such as anthropometric measurements and biochemical parameters were recorded and compared after 3 months to determine the effect of therapy. Descriptive analysis using a parametric test was used to assess the change in biochemical parameters and a non-parametric test was applied to find out the association between non-pharmacological and pharmacological approaches.

RESULTS

Out of 177 patients, 67.2 % were male and 32.8% were female with the mean age ±SD of 46.8 ± 12.06 years. Mean ± SD weight and body mass index of the patients were changed from 74.88 ± 11.61 kg to 72.37 ± 11.61 kg and from 28.41 ± 4.02 kg/m to 27.31 ± 4.58 kg/m respectively which was found to be statistically significant. There was a significant change in all the biochemical parameters with the -value < 0.05 through both non-pharmacological and pharmacological approaches.

CONCLUSION

Nonalcoholic fatty liver disease management through exercise and pharmacotherapy shows significant improvement in biochemical parameters indicating that alone or in combination with both approaches play an effective role in treating nonalcoholic fatty liver disease.

摘要

目的

非酒精性脂肪性肝病是一种新兴的肝脏疾病,影响着20%-30%的人群,给全球公共卫生带来负担,并且与多种疾病的病因相关。除了运动之外,基于临床证据,几种药物也被用于患者治疗,尤其是维生素E,一种有效的抗氧化剂,可减少导致非酒精性脂肪性肝病发生和发展的氧化应激。本研究旨在评估运动和药物治疗对非酒精性脂肪性肝病的影响。

设计

在一家肝脏诊所进行了为期3个月的前瞻性随访研究,采用目的抽样法。记录人体测量和生化参数等基线特征,并在3个月后进行比较,以确定治疗效果。使用参数检验进行描述性分析,以评估生化参数的变化,并应用非参数检验来找出非药物和药物治疗方法之间的关联。

结果

177例患者中,67.2%为男性,32.8%为女性,平均年龄±标准差为46.8±12.06岁。患者的平均±标准差体重和体重指数分别从74.88±11.61kg变为72.37±11.61kg,从28.41±4.02kg/m²变为27.31±4.58kg/m²,差异具有统计学意义。通过非药物和药物治疗方法,所有生化参数均有显著变化,P值<0.05。

结论

通过运动和药物治疗管理非酒精性脂肪性肝病,生化参数有显著改善,表明单独或联合这两种方法在治疗非酒精性脂肪性肝病中均发挥有效作用。

相似文献

1
Effect of exercise and pharmacotherapy on non-alcoholic fatty liver disease.
SAGE Open Med. 2024 Jan 25;12:20503121241227090. doi: 10.1177/20503121241227090. eCollection 2024.
3
Physical activity support or weight loss counseling for nonalcoholic fatty liver disease?
World J Gastroenterol. 2014 Aug 7;20(29):10128-36. doi: 10.3748/wjg.v20.i29.10128.
4
AGA Clinical Practice Update: Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review.
Gastroenterology. 2022 Sep;163(3):764-774.e1. doi: 10.1053/j.gastro.2022.06.023. Epub 2022 Jul 14.
5
Effect of berberine and bicyclol on Chinese patients with nonalcoholic fatty liver disease: a retrospective study.
Postgrad Med. 2022 Jun;134(5):507-515. doi: 10.1080/00325481.2022.2063568. Epub 2022 Apr 26.
7
Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
World J Gastroenterol. 2015 Apr 7;21(13):3777-85. doi: 10.3748/wjg.v21.i13.3777.
8
10
[Effect of aerobic exercise and resistance exercise in improving non-alcoholic fatty liver disease: a randomized controlled trial].
Zhonghua Gan Zang Bing Za Zhi. 2018 Jan 20;26(1):34-41. doi: 10.3760/cma.j.issn.1007-3418.2018.01.009.

引用本文的文献

1
Healthy Lifestyle and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Study of the Efficacy of Fatty Liver Regression.
Clin Transl Gastroenterol. 2025 Feb 1;16(2):e00806. doi: 10.14309/ctg.0000000000000806.

本文引用的文献

2
Changing clinical management of NAFLD in Asia.
Liver Int. 2022 Aug;42(9):1955-1968. doi: 10.1111/liv.15046. Epub 2021 Sep 7.
7
Drug Development for Nonalcoholic Fatty Liver Disease: Landscape and Challenges.
J Clin Exp Hepatol. 2019 Jul-Aug;9(4):515-521. doi: 10.1016/j.jceh.2019.03.002. Epub 2019 Mar 13.
8
Phase 3 drug pipelines in the treatment of non-alcoholic steatohepatitis.
Hepatol Res. 2019 Nov;49(11):1256-1262. doi: 10.1111/hepr.13425. Epub 2019 Oct 25.
9
Effect of vitamin E in non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomised controlled trials.
Postgrad Med J. 2019 Nov;95(1129):601-611. doi: 10.1136/postgradmedj-2018-136364. Epub 2019 Aug 21.
10
High prevalence of non-alcoholic fatty liver disease among healthy male blood donors of urban India.
JGH Open. 2019 Jan 16;3(2):133-139. doi: 10.1002/jgh3.12117. eCollection 2019 Apr.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验